EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19)

Roghayyeh Baghban, Abdolmajid Ghasemian, Shirin Mahmoodi

Archives of Microbiology · 2023

DOI: 10.1007/s00203-023-03480-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Archives of Microbiology, 2023. Verfasst von Roghayyeh Baghban und 2 weiteren Autor:innen. Beteiligte Einrichtung: Poostchi Ophthalmology Research Center, Department of Ophthalmology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Hauptthemen laut MEDLINE: Vaccines, DNA, COVID-19. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The coronavirus disease 2019 (COVID-19) pandemic has infected 673,010,496 patients and caused the death of 6,854,959 cases globally until today. Enormous efforts have been made to develop fundamentally different COVID-19 vaccine platforms. Nucleic acid-based vaccines consisting of mRNA and DNA vaccines (third-generation vaccines) have been promising in terms of rapid and convenient production and efficient provocation of immune responses against the COVID-19. Several DNA-based (ZyCoV-D, INO-4800, AG0302-COVID19, and GX-19N) and mRNA-based (BNT162b2, mRNA-1273, and ARCoV) approved vaccine platforms have been utilized for the COVID-19 prevention. mRNA vaccines are at the forefront of all platforms for COVID-19 prevention. However, these vaccines have lower stability, while DNA vaccines are needed with higher doses to stimulate the immune responses. Intracellular delivery of nucleic acid-based vaccines and their adverse events needs further research. Considering re-emergence of the COVID-19 variants of concern, vaccine reassessment and the development of polyvalent vaccines, or pan-coronavirus strategies, is essential for effective infection prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccines, DNACOVID-19HumansNucleic Acid-Based VaccinesCOVID-19 VaccinesBNT162 VaccineSARS-CoV-2RNA, Messenger

Stichwörter der Autor:innen

Coronavirus disease 19ImmunityNucleic acid–base vaccinesProtection

Substanzen

GX-19N vaccineVaccines, DNANucleic Acid-Based VaccinesCOVID-19 VaccinesBNT162 VaccineRNA, Messenger

Autor:innen und Institutionen

  • Poostchi Ophthalmology Research Center, Department of Ophthalmology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran.
  • Department of Medical Biotechnology, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran. shirinm64@gmail.com.

Zitieren

APA

Baghban, R., Ghasemian, A., & Mahmoodi, S. (2023). Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19). Archives of Microbiology. https://doi.org/10.1007/s00203-023-03480-5

Vancouver

Baghban R, Ghasemian A, Mahmoodi S. Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19). Archives of Microbiology. 2023. doi:10.1007/s00203-023-03480-5

BibTeX
@article{Baghban2023,
  author = {Baghban, Roghayyeh and Ghasemian, Abdolmajid and Mahmoodi, Shirin},
  title = {Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19)},
  journal = {Archives of Microbiology},
  year = {2023},
  doi = {10.1007/s00203-023-03480-5}
}
Kostenlos starten →